Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children [Yahoo! Finance]
Vivos Therapeutics, Inc. (VVOS)
Company Research
Source: Yahoo! Finance
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.'s (NASDAQ: VVOS ) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children Recent published studies report up to 10.1 million U.S. children (ages 6-17) are estimated to suffer from pediatric OSA. Vivos' DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective. It is designed to reduce nighttime snoring and treat moderate to severe obstructive sleep apnea in children aged 6 to 17. The Vivos device is intended for those diagnosed with snoring and/or OSA requiring orthodontic treatment. Vivos believes this breakthrough regulatory clearance represents a huge opportunity to capture significant market share. Further, Vivos believes it can immediately leverage this FDA clearance by quickly integrating pediatric care into its new provider-based marketing and distribution model and scale revenue relatively quickly w
Show less
Read more
Impact Snapshot
Event Time:
VVOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VVOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VVOS alerts
High impacting Vivos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VVOS
News
- Vivos Therapeutics, Inc. (NASDAQ: VVOS) had its "buy" rating re-affirmed by analysts at Ascendiant Capital Markets. They now have a $6.60 price target on the stock.MarketBeat
- Vivos Therapeutics, Inc. (NASDAQ: VVOS) had its price target lowered by analysts at Alliance Global Partners from $8.25 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewswire
VVOS
Earnings
- 11/14/24 - Beat
VVOS
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- 11/14/24 - Form 10-Q
- VVOS's page on the SEC website